[A field trial of recombinant human interferon alpha-2b for nasal spray to prevent SARS and other respiratory viral infections]

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Sep;19(3):216-9.
[Article in Chinese]

Abstract

Objective: To study the preventive effect of recombinant human interferon alpha-2b for nasal spray against SARS and other common respiratory viral infections by serum-epidemiological method.

Methods: A randomized, placebo-controlled, double-blind field trial study in populations with 14,391 persons from SARS prevalent cities or provinces in China during May-Jun, 2003 and Dec-Apr, 2004. Interferon alpha-2b was given twice per day, once 9 x 10(5) IU by nasal spray for 5 days. Serum samples were taken at 15 days after last administration. Serological tests included SARS IgG antibody and IgM antibodies against influenza B, parainfluenza virus types 1-3, adenovirus type 3, 7 and respiratory syncytial virus by using commercial ELISA kits.

Results: No statistically significant difference in serum SARS IgG antibody positive rate was found between the interferon and control groups among 2,757 serum samples. On the other hand, after using interferon, all four respiratory viruses (parainfluenza virus types 1-3 influenza B, adenovirus types 3, 7 and respiratory syncytial virus) in interferon group had lower IgM antibody positive rates than those in control group. Among them there were statistically significant differences between the interferon and control groups for parainfluenza virus, influenza B and adenovirus. The preventive efficacy of interferon against four respiratory viruses was different, from high to low, the rank was Flu B (66.76%), parainfluenza types 1-3 (66.75%), RSV (39.61%) and adenovirus (32.86%). The average preventive efficacy was 50.27%.

Conclusion: The recombinant human interferon alpha-2b for nasal spray could decrease the rates of common respiratory viruses infection in the selected population.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Adult
  • Antibodies, Viral / blood
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use
  • Double-Blind Method
  • Humans
  • Immunoglobulin G / blood
  • Immunoglobulin M / blood
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use*
  • Recombinant Proteins
  • Respiratory Tract Infections / blood
  • Respiratory Tract Infections / prevention & control*
  • Respiratory Tract Infections / virology
  • SARS Virus / drug effects
  • SARS Virus / immunology
  • Severe Acute Respiratory Syndrome / blood
  • Severe Acute Respiratory Syndrome / chemically induced
  • Severe Acute Respiratory Syndrome / prevention & control*
  • Treatment Outcome
  • Young Adult

Substances

  • Antibodies, Viral
  • Antiviral Agents
  • Immunoglobulin G
  • Immunoglobulin M
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins